Year None20212020201920182017 Turning Point Therapeutics to Participate in Upcoming Investor Conferences Nov 10, 2021 Turning Point Therapeutics Reports Third-Quarter Financial Results, Provides Operational Updates Nov 09, 2021 Turning Point Therapeutics Announces Appointment of Adam Levy as Senior Vice President of Investor Relations Nov 08, 2021 Turning Point Therapeutics to Host Third Quarter 2021 Conference Call Nov 02, 2021 Turning Point Therapeutics Presents Early Clinical Data for Repotrectinib From Care Study in Pediatric and Young Adult Patients at SIOP 2021 Virtual Congress Oct 23, 2021 Turning Point Therapeutics and EQRx Announce Clinical Collaboration to Evaluate Elzovantinib in Combination with Aumolertinib in Patients with EGFR Mutant Met-Amplified Advanced Non-Small Cell Lung Cancer Oct 13, 2021 Turning Point Therapeutics to Present Early Clinical Data for Repotrectinib From the CARE Study in Pediatric and Young Adult Patients at SIOP 2021 Virtual Congress Oct 11, 2021 Turning Point Therapeutics Presents TRIDENT-1 Study Clinical Data for Repotrectinib in NTRK+ Advanced Solid Tumors in Plenary Session at 2021 AACR-NCI-EORTC Conference Oct 08, 2021 Turning Point Therapeutics Presents Updated Preliminary Clinical Data for Repotrectinib and Elzovantinib (TPX-0022) at 2021 AACR-NCI-EORTC Conference and Provides Regulatory Updates Oct 07, 2021 Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients with NTRK-Positive, TKI-Pretreated Advanced Solid Tumors Oct 04, 2021 Pagination Current page 1 Page 2 Page 3 Page 4 Next page next › Last page last »
